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Abstract: 
This report summarizes findings related to the psychometric properties (internal consistency and 
construct validity) of the Pittsburgh Sleep Quality Index (PSQI) and discusses issues related to 
its use based on data from two clinical studies with diverse samples of cancer patients. Subjects 
completed a questionnaire that included the PSQI, the Schwartz Cancer Fatigue Scale, and 
specific demographic, disease, and treatment variables. There were complete data on 170 (of 
214) cases in Study 1 and 249 (of 259) cases in Study 2. The Cronbach’s alpha for the Global 
Sleep Quality scale was 0.81 in Study 1 and 0.77 in Study 2. A comparison of Global Sleep 
Quality in two contrasting groups with low and high fatigue yielded statistically significant 
differences in both samples. Psychometric evaluation supports its internal consistency reliability 
and construct validity. However, the scoring is rather cumbersome and raises questions regarding 
level of measurement and appropriate analysis techniques.  




Sleep disturbances can seriously influence physical and mental well-being as well as quality of 
life. These effects are often more pronounced in individuals who are facing the multiple 
consequences of a serious and life- threatening illness such as cancer. There is some evidence 
that cancer patients have more problems sleeping than healthy individuals and that the degree of 
difficulty in initiating and maintaining sleep for cancer patients may even be as high as in 
suicidal patients or known insomniacs.1 Sleep deprivation can have profound physical effects 
including fatigability, pain intolerance, and decreased immune functioning as well as emotional 




Research on sleep in cancer patients has been limited by the lack of an effective measurement 
tool for clinical trials. There are few empirical data using psychometrically sound measures 
about the real prevalence and nature of sleep
s 
disturbances in cancer patients.
 4
 It is not known 
which types of patients are more likely to have significant problems and whether there is a 
relationship between sleep disturbances and demographic characteristics, type of cancer, extent 
of disease, or type of treatment. It has been proposed that other common symptoms in cancer 
patients such as pain, fatigue, anxiety, and depression may be associated with sleep disturbances 
but the strength and significance of these relationships is not known. Advancing the science in 
this area, including clinical trials of interventions to improve sleep, will require consistent use of 
measures with established reliability and validity in cancer patients. The purpose of this report is 
to summarize findings related to the psychometric properties of a self- report tool, the Pittsburgh 
Sleep Quality Index (PSQI), and to discuss issues related to its use based on data from two 
clinical studies with diverse samples of cancer patients. 
 
Sleep Measurement: Polysomnography and Actigraphy 
There are numerous approaches to sleep measurement that range in expense and ease of use. 
Tools that measure various aspects of sleep include polysomnography, actigraphy, and self-
reports including sleep logs and questionnaires. Polysomnography, or all-night sleep recordings, 
is considered the most accurate measure of sleep and yields measures of specific sleep stages. 
Polysomnography monitors sleep-related physiologic parameters such as respiratory, 
neuromuscular, cardiac, gastrointestinal, and endocrine functions.
5
 Parameters may be measured 
by electroencephalogram (EEG) (the core of polysomnography), electrooculogram (EOG), 
electrocardiogram (ECG), or electromyogram (EMG) readings. Although polysomnography is 
the physiologic ―gold standard‖ to monitor sleep, it is most often utilized in a sleep lab that can 
be expensive, inconvenient, cumbersome, or uncomfortable. These reasons may explain why no 
clinical studies in cancer patients have used polysomnography. 
 
An alternative but less inexpensive approach is the use of actigraphy, an instrument that records 
a patient’s movement pattern over a period of time. The wrist actigraph is a small device that can 
be worn on the wrist or leg.
6
 Movement data from internal motion sensors is transferred to a 
computer for an analysis of standard descriptors of sleep and wake periods. Each actigraphy 
wristwatch costs about US$ 1,000 and data management and interpretation can be time-intensive, 
thus its applicability in large-scale clinical trials may be limited. 
 
Recent research with cancer patients has used actigraphy. Miaskowski and Lee reported that 
cancer patients (n = 24) receiving radiation therapy experienced significant sleep disturbances as 
measured by actigraphy. Furthermore, those who were given a higher proportion of their 
radiation treatment dose reported more sleep problems.
7
 Berger and Farr used actigraphy to study 
72 women receiving chemotherapy. They reported an increased number of nighttime awakenings 
that were associated with increased fatigue.
8 
 
Sleep Measurement: Self-Report 
Self-report measures are the most common approach to measuring sleep and include sleep 
diaries, sleep logs, and questionnaires. These non-physiologic measures of sleep have multiple 
utility and can allow comparison between sleep parameters, monitor adherence to therapy, 
facilitate longitudinal data collection, evaluate treatment progress, monitor symptoms, and 
promote self management.
9
 Sleep logs can be used to give a day-to-day account of sleep 
activities 24 hours per day over a period of time. The advantages of self reports include their ease 
of use, convenience, low expense, reflection of the natural setting, relative non- obtrusiveness, 
and recording of the person’s perceived sleep experience. Disadvantages of self-reports consist 
of their subjectivity; they may also be burdensome if used daily. They are subject to reporting-
bias and may yield missing data when respondents do not answer all items or inaccurate data if 
participants fail to complete them in a timely way.9,10 
 
Numerous clinical studies on side effects of cancer treatment, cancer pain, and quality of life in 
cancer patients use self-report measures. In a recent review of 15 prevalence studies in diverse 
cancer populations, most reported findings from a single question embedded in another 
instrument. Between 30–50% of patients reported sleep difficulties of some type.3 In a more 
comprehensive, 82-item, investigator- designed survey of 150 patients with breast and lung 
cancer, Engstrom et al. found that 44% reported ―a problem with sleep disturbances‖ during the 
past month. In a follow-up interview with those experiencing problems, 57% reported the 
severity of the sleep disturbance as at least moderate in intensity.11 In a small comparative study 
of subjective reports of sleep patterns of cancer patients to a control group, cancer patients were 
three times more likely to experience sleep difficulties; specifically, many faced increased 
difficulty with sleep onset.
12 
 
The Pittsburgh Sleep Quality Index 
The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep 
quality and quantity. The original version was designed to measure sleep reports over a one- 
month interval.
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 The19-item self-report questionnaire yields 7 component scores: subjective 
sleep quality, sleep latency, duration, habitual sleep efficiency, sleep disturbances, use of 
sleeping medication, and daytime dysfunction. There are five additional questions that are 
completed by a bed partner if there is one. These are not used in the scoring. A Cronbach’s alpha 
of 0.83 was reported for the Global Sleep Quality scale. A Global Sleep Quality score greater 
than 5 discriminated between good and poor sleepers and yielded a diagnostic sensitivity of 
89.6% and specificity of 86.5%.
13,14



















There is limited research on the use of the PSQI with cancer patients: one study with 15 patients 
and a historical control and one study limited to women with breast cancer following treatment. 
Owen et al. used the PSQI to compare a small sample of 15 cancer patients to 52 healthy 
individuals.
 22
 They found that the cancer patients had significantly poorer overall sleep quality 
and scored significantly worse on 5 of the 7 component scores. Carpenter and Andrykowski 
found in their research of the psychometric evaluation of the PSQI that it demonstrated utility for 
self-administration, internal consistency reliability (alpha = 0.80 across all diagnostic groups), 
and construct validity across a variety of clinical populations, including a group of 102 women 
with breast cancer receiving routine follow-up care.
 23
 They recommended that a cut-off score of 
>8 (vs. 5 as recommended by the tool developers) may be more appropriate to determine poor 
sleep in clinical populations. 
 
Evidence to support the reliability, validity, and sensitivity of the PSQI in patients with diverse 
types of cancer and undergoing active treatment is lacking and essential to support its use as an 
outcome measure in future clinical studies. This report summarizes an analysis of two clinical 
studies and includes: 1) discussion of missing data and issues related to scoring and feasibility; 
2) an evaluation of reliability using an item analysis and reliability analysis to determine internal 
consistency; and 3) an assessment of construct validity by contrasting sleep quality in two 
groups—one with low and one with high fatigue using independent group t-tests. Data for these 
analyses come from two clinical studies with diverse samples of cancer patients with a variety of 
primary diagnoses and including patients receiving radiation therapy and chemotherapy. Both 




This cross-sectional study was designed to evaluate the psychometric properties (i.e., internal 
consistency and construct validity) of the PSQI (adapted for a one-week time interval) in a 
heterogeneous sample of cancer patients. The study used a prospective, consecutive sampling 
approach. All patients who were receiving care in three settings (outpatient oncology, radiation 
therapy, and inpatient oncology) at the University of Utah (UU) in Salt Lake City, Utah, during a 
designated time period were screened for study eligibility and invited to complete a 
questionnaire. Completion of the questionnaire implied voluntary consent to participate. The 
symptom questionnaire included several tools but those reported here include the PSQI
13
 and the 
Schwartz Cancer Fatigue Scale (SCFS).
24
 The SCFS is a short, 6-item instrument that asks the 
respondent to rate ―how much has fatigue made you feel (e.g. tired)?‖ on a five-point verbal 
numeric scale with 1 being not at all and 5 being extremely. Two subscales can be computed that 
measure physical and perceptual fatigue. The reliability and validity 
24.25
 of this tool have been 
established. Both tools were framed within the context of ―the past week.‖ 
 
Of those who were eligible, 214 patients consented to participate (radiation therapy n = 81, 
outpatient oncology clinic n = 86, and inpatient oncology unit n = 47). The study demographic 
characteristics are summarized in Table 1. Forty-nine percent were female and age ranged from 
14 to 88 years, with a mean age of 53 years. Racial/ethnic diversity was limited; 92.3% were 
Caucasian, reflective of the state’s population at that time. The patients had multiple types of 
cancer as a primary diagnosis (see Table 2); 19.6% had breast cancer and 47.1% of the patients 
had advanced disease. 
 
Study 2 
The second longitudinal study addressed similar aims by a secondary analysis using data from a 
randomized clinical trial to compare an energy conservation/activity management 
 
 
(ECAM) intervention with an attentional control group for the management of cancer treatment-
related fatigue.
 26
 The intervention consisted of structured information about energy conservation 
and activity management combined with training in skills for coping with fatigue in an 
emotionally supportive context. The attentional control group received nutrition information 
unrelated to fatigue or treatment and was designed to provide the amount of instruction 
equivalent to the ECAM intervention. The intervention was delivered by telephone by a nurse 
counselor. Participants received three phone calls to discuss educational materials sent in the 
mail and consequently developed and implemented an action plan. 
 
The sample included men and women, over age 18, who were initiating treatment for breast, 
lung, colorectal, cervical, testicular, prostate, and lymphoma cancers. The treatment was for cure 
or local control and involved at least three cycles of chemotherapy, 5–6 weeks of radiation 
therapy treatments, or concurrent radiation and chemotherapy. This study was implemented at 
two clinical sites; Fox Chase Cancer Center (FCCC) in Philadelphia, Pennsylvania and the 
Huntsman Cancer Institute at the University of Utah (UU) in Salt Lake City, Utah. In addition to 
the PSQI, eight other instruments were utilized in this study, including the Schwartz Cancer 
Fatigue Scale.
 24
 The PSQI questions were framed within the context of the sleep experience 
during the past month, which is the original version. Data were collected at three time points, 
which varied by treatment regimen. In the chemotherapy and concurrent group, measures were at 
baseline and 48 hours following the second and third chemotherapy administrations. In the radia-
tion therapy group, measures were at baseline, during the last week of treatment, and one month 
following treatment. Time 3 data were utilized in this analysis. 
 
Research staff initially screened individuals who were diagnosed with eligible cancers and 
scheduled for initial evaluations. They then explained the study objectives and procedures to 
eligible individuals; those interested provided written consent to participate. The individual then 
completed the baseline questionnaires. If contact was made by phone, questionnaires and consent 
forms were mailed to participants. After reviewing returned questionnaires, research staff called 
participants if responses were not complete. 
 
The sample at Time 3 included 259 cancer patients aged 26 to 83 years, with a mean age of 56.6 
years. One hundred twenty-nine (49.8%) were receiving radiation therapy and 130 (50.2%) were 
receiving chemotherapy or concurrent therapy. The study demographic characteristics are 
summarized in Table 1. More (89.2%) were female and 90.7% were Caucasian. Although all 
target cancer diagnoses were represented (see Table 2), the majority (78.8%) had breast cancer. 
 
RESULTS 
There are 19 individual questions in the PSQI. The scoring of these questions transforms them 
into seven components, each ranging from 0 to 3, with a higher score representing poorer sleep 
quality. Some questions are simply re- coded and others combine 2–9 questions and then recode 
responses to yield a 0 to 3 scale. 13 The sum of these 7 components yields a Global Sleep 
Quality score ranging from 0 to 21. The scoring is prescribed in the original methodological 
paper but has several glitches, such as overlapping categories. Clarifications to the scoring as 
used in these analyses are detailed in Appendix 1. 
 
In order to compare the psychometric properties of the PSQI with reports in other populations, 
each of the seven component scores is treated as an ―item‖ in the analysis. In addition, the results 
from several of the original questionnaire variables are reported as they may be more clinically 
relevant and sensitive to change in the cancer patient population. 
 
Analysis of Missing Data 
The first step in the analysis was to evaluate individual questions to identify the pattern of 
missing data. Unless corrected in the analysis, each missing question can result in a missing item 
and a missing Global Sleep Quality score. A large amount of missing data can influence the 
reliability of the tool and bias the findings. The number and percent missing for each component 
are summarized in Table 3. The cumulative effect in the ability to compute the Global Sleep 
Quality score was marked in Study 1, as 21% of cases were lost. This was decreased to 4.2% in 
Study 2, as participants were called to follow-up on missing questions. 
 
Item and Reliability Analysis 
The second step in the analysis was to evaluate the range and variance of responses to each item, 
that is, component score, following the recoding to 0–3. Responses included the range of all 
possible scores for each of the seven items. The Global Sleep Quality score ranged from 0 to 21 
in Study 1 and 1 to 19 in Study 2. The highest possible score would be 21. The means and 
standard deviations for each sample are summarized in Table 4. In Study 1, the mean component 
scores ranged from 0.99–1.48; in Study 2, the means ranged from 0.85–1.47. The item-to-item 
correlation matrix was examined to identify items with low (less than 0.30, indicating minimal 
contribution) or high (greater than 0.70, indicating redundancy) correlations. There were no 
item–item correlations greater than 0.70, indicating little redundancy in the items. In Study 1, six 
correlations were less than 0.30; three were for component 6, Use of Sleeping Medication, and 
three were with component 7, Daytime Dysfunction. These 
 
 
may represent distinct concepts, but it would be difficult to factor analyze as these are only 
single questions. In Study 2, the pattern was similar except there were also three low correlations 
with component 5, Sleep Disturbances. 
 
A reliability analysis of the 7 component score items was conducted using SPSS 11.0. The 
corrected item-to-total (i.e., Component-toGlobal) correlations and Cronbach alpha coefficients 
if the item were deleted are summarized for each sample in Table 5. In Study 1, the Component-
to-Global correlations ranged from 0.38–0.64. In Study 2, the Component-to-Global correlations 
ranged from 0.32–0.63. In both, components 6 and 7 were lowest. The overall scale alpha was 
0.804 in Study 1 and 0.770 in Study 2. The alpha increased minimally by deleting component 6 ( 
Use of Sleeping Medication) in Study 2. 
 
Validity Analysis 
The construct validity was examined by comparing the Global Sleep Quality scores in two con-
trasting groups: low fatigue and high fatigue. The mean score on the SCFS (possible 1 low to 5 
high) was categorized into two groups. Those with a fatigue score from 1 to 3 were categorized 
as low and from 3.1 to 5 as high. Scores on the PSQI Global Sleep Quality were compared using 
independent t-tests (Table 6). The findings indicate that the Global Sleep Quality score was 
significantly higher (indicating poorer sleep) in the high fatigue groups. This was true in both 
samples and supports the construct validity of the PSQI. 
 
DISCUSSION 
In order to effectively study the sleep problems that cancer patients experience, it is necessary to 
identify valid and reliable tools to measure sleep that can be easily administered in the clinical or 
home setting. The PSQI is a self-administered questionnaire that collects data regarding multiple 




When self-administered, there can be a significant amount of missing data unless the ques-
tionnaire is reviewed for completion and missing items are revisited with the respondent. In 
Study 1, the question about ―usual bed time‖ had a high percent missing. Many people would 
write in yes versus indicating a time. This resulted in an inability to accurately compute Sleep 
Efficiency. Several analytic strategies can be applied to not lose cases in the scoring. For 
example, in computing the Sleep Disturbances, the sum was computed by recoding missing 
items as 0 so all subjects with at least one response would have a score. In computing the Global 
Sleep Quality, several approaches can be applied. It is possible to impute a mean score for a 
missing component based on the other components. An alternate approach was used in Study 2. 
A Global Sleep Quality computation was allowed if at least 5 of the 7 components were present. 
A mean of the non-missing components was computed and the result multiplied by 7 to give a 
comparable score. The mean sum in using this approach was 7.308 with 259 cases, as compared 
to 7.297 with 249 cases when only complete cases were included. 
There are a few other practical points of interest. Because patients report time data (e.g., time 
that you usually go to bed), it is wise to determine the type of time and format that will be used 
to enter the data a priori. Military time is recommended. In addition, it is useful to establish a 
system to cross check the multiple computerized calculations. For example, importing data into 
an Excel spread sheet can allow for cross-checking the hours in bed and sleep efficiency 
calculations. This approach allows easier detection of problems that may be formulaic or unusual 
cases in which original data should be verified. 
 
The evidence from these two studies supports the internal consistency (reliability) of the PSQI 
in these two samples of cancer patients. These findings are similar to those reported in the tool 
development in which the Cronbach’s alpha was 0.83
13
 and in two other studies in which the 
alpha ranged from 0.80 to 0.83.
22,23
 Each of the seven components contributes to the mea-
surement of the overall construct of sleep quality. Another similar finding is that the largest 
item-total (Component-to-Global) coefficients were found for habitual sleep efficiency and 
sleep quality. In these studies, Use of Sleeping Medication and Daytime Dysfunction had the 
lowest Component-to-Global correlations, while in the original study, Sleep Disturbances had 
the lowest item-total (Component-to-Global) correlation. Additional research to replicate these 
findings and to test sensitivity and test–retest reliability in cancer patients is recommended. 
The findings from these two studies also support the construct validity of the PSQI. Using a 
contrasting groups approach, there were significant and clinically relevant differences in Global 
Sleep Quality between groups with low and high fatigue in both samples. This finding is similar 
to the significant difference in sleep quality found by Buysse et al between controls and patients 
with depression.
 13
 Additional research might consider factor analysis to evaluate whether the 
PSQI only measures one construct or has subscales. This approach seems reasonable 
conceptually (e.g., is Sleep Efficiency different than Sleep Latency?), but is limited 
mathematically by the 7 component scores that are built into the scoring of tool and limited 
number of total questions (n = 19). Most components, except Sleep Disturbances, are based on 
one or two questions. 
One limitation of the scoring approach used in the PSQI is that the level of measurement and 
potential variance are decreased as questions are combined and rescored. This is true in 
particular with Minutes to Fall Asleep and Sleep Efficiency (a computed percent: hours asleep/ 
hours in bed), which are interval level data. Another problem with Sleep Efficiency is that the 
computed percent may be greater than 100%. This was true for 10 cases (3.9%) in Study 2. This 
phenomena is explainable as subjects answer individual questions (e.g., what time do you 
usually go to bed) that are used to compute sleep efficiency with an average for a week or 
month. This does not really pose a problem in the scoring as all Sleep Efficiency ratings greater 
than 85% received a score of ―0‖. However, if Sleep Efficiency is used as a percentage variable, 
these scores will inflate the mean. One approach is to recode values greater than 100% to equal 
to 100%. The scoring scheme also yields a loss of data in regards to Sleep Disturbances. This 
item could range from 0 to 27 and is reduced to 0–3 in the scoring, thus losing sensitivity. In 
cancer patients, specific causes of sleep disturbance, such as pain, are relevant clinically and as 
a confounding variable in research. An alternative approach is to evaluate these items as 
outcomes independent of the components or scoring instructions. 
In conclusion, the PSQI is a relatively easy-to-administer tool that can measure sleep quality 
over a period of time. Psychometric evaluation supports its internal consistency (reliability) and 
construct validity in cancer patients. The scoring is rather cumbersome and raises questions re-
garding level of measurement and appropriate analysis techniques. Additional research should 
examine the test-retest reliability of the PSQI and sensitivity to change, and further evaluate its 
construct validity. Research in cancer patients with greater ethnic and racial diversity is 
recommended to further support its use as an outcome measure in clinical studies. 
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